AdAlta Ltd’s Post

📢 We’re pleased to share our Q3 2024 financial results and recent operational progress. Some of the highlights are: 🔹 Strong Financial Position: With a cash balance of $18.5M, Allarity is well-positioned financially. 🔹 Enhanced Leadership: We welcomed Jeremy R. Graff, Ph.D., as President and Chief Development Officer, and Jose Iglesias, M.D., as Consultant Chief Medical Officer. Their expertise is invaluable in steering our lead candidate, stenoparib, toward regulatory and clinical success. 🔹 Stenoparib Milestones: Two patients in our Phase 2 trial for advanced ovarian cancer exceeded one year on treatment, underscoring stenoparib’s potential to provide a durable response for those with few other options. 🔹 European Patent for DRP® Companion Diagnostic: Allarity was granted a European patent for our DRP® technology specific to stenoparib, bolstering our IP strategy in key markets like the EU, U.S., and Asia. Read more in our full release: https://lnkd.in/efTpydwg #CancerTreatment #Stenoparib #PrecisionMedicine #ClinicalTrials #Oncology

🗞 IN THE NEWS: In a clinical trial at NIH’s National Cancer Institute (NCI), researchers tested the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (called ViPOR) in 50 patients with DLBCL, the most common type of lymphoma. The treatment shrank tumors substantially in 26 of 48 (54%) evaluable patients, with 18 (38%) of those patients’ tumors disappearing entirely, known as a complete response. At two years, 36% of all patients were alive and 34% were free of disease. These benefits were seen mainly in people with two specific subtypes of DLBCL. ➡ Read more in this piece by MedPage Today: https://lnkd.in/eK75QQyd Additional outlets that have covered ViPOR include Healio, European Pharmaceutical Review, HealthDay News, Clinical Trials Arena, etc. #CancerResearch #Lymphoma #ClinicalTrial #Health #Medicine

📢 Update: PMP Cell Cultures Delivered! 🚀 At Bina Therapeutics, we’re pleased to share an important milestone: The arrival of Pseudomyxoma Peritonei (PMP) cell cultures on 23rd December. 🚚 👉These ultra-rare cell lines will play a vital role in supporting preclinical validation, keeping us on track in our mission to develop innovative treatments for this challenging disease. 🔬 ✨ The journey is far from over but the progress so far has been incredible. 🙌 👉 Read the full update here: https://lnkd.in/eZFSsHRN #PMPResearch #RareDiseases #PseudomyxomaPeritonei

As 2024 comes to a close, we reflect on a year of transformative progress at Avidity as we work towards our vision to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics. This year, we reported unprecedented data for #DMD44, #DM1, and #FSHD and advanced each of our neuromuscular programs in clinical trials. We were also excited to announce the expansion of our AOC platform beyond rare skeletal muscle diseases, including new precision #cardiology candidates for rare genetic cardiomyopathies and unveiling next-generation technology innovations. Looking ahead, we are continuing to advance our programs and build a global integrated biopharmaceutical company to bring these potential therapies to people living with serious rare diseases as quickly as possible. We are deeply grateful for our entire community—the patients and families who inspire us, the advocates who amplify vital voices, and the researchers and partners who share our vision for transformative therapies. To our #BeAVID team—thank you for your dedication, innovation, and hard work. Wishing everyone a wonderful holiday season and a happy New Year!

As we celebrate #RNADay today, we want to recognize the scientists and researchers who continue to drive innovation in the RNA field. As a leader in RNA-based therapeutics, we are proud to leverage our proprietary Antibody Oligonucleotide Conjugates (AOC) platform which combines the targeting precision of antibodies with the therapeutic potential of oligonucleotides to advance our clinical development programs for three rare muscle diseases: #DM1, #FSHD, and #DMD. Over the last year, we have shared exciting data across all three clinical programs, reaffirming the potential of our AOC platform to profoundly improve people’s lives. Today we want to recognize and celebrate the important efforts of our #BeAVID team as we work to realize our vision to revolutionize RNA therapeutics and bring treatments to patients as quickly as possible. Learn more about our AOC platform and our work in the RNA field in a recent Drug Development & Delivery article, featuring our Distinguished Scientist and Strategic Leader, Art Levin, PhD. Read the article: https://lnkd.in/eWBrJiAM

Our portfolio company HAYA Therapeutics has been recognized by Labiotech.eu as one of the top 18 biotech startups in Switzerland, spotlighting its innovative approach to targeting non-coding RNAs to combat fibrotic diseases and age-related conditions: https://lnkd.in/gnPbAhQ As reported by The Financial Times, a groundbreaking anti-aging therapy that mimics regenerative processes seen in axolotl salamanders has shown promise in extending the lifespan of mice by 25%. Read more about the treatment that targets the pro-inflammatory protein IL-11: https://lnkd.in/guvdqyFH New hires at our portfolio companies: HAYA Therapeutics welcomes Eric Adam as their new COO, bringing his extensive experience from the pharmaceutical and diagnostics industries to support their growth and scientific exploration. Meanwhile, Auron Therapeutics, Inc. introduces Serge Messerlian to their board, enhancing their leadership as they advance their innovative cancer therapeutics platform. #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

🚀 $TELO: Telomir Pharmaceuticals, Inc. Confirms Age Reversal, Increased Longevity, and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 🚀 I’m excited to share a groundbreaking moment for Telomir. Our preclinical results for Telomir-1 demonstrate its incredible potential to: ✅ Extend life ✅ Preserve health ✅ Turn back the biological clock 🗨️ "The results we are seeing with Telomir-1 mark an important step forward in our journey to potentially reverse aging in humans. This study confirms that Telomir-1 can extend life, preserve health, and turn back the biological clock. We are very excited about the potential applications as we progress toward human clinical trials." – Erez Aminov This is a transformative milestone in the science of aging. Stay tuned as we continue to push boundaries and redefine what’s possible for longevity and healthspan. 👉 Read the full press release: https://lnkd.in/eDtTiw28 #AgeReversal #Longevity #Healthspan #BiotechInnovation #Telomir1 #Pharmaceuticals #Research #Cancer #Diabetes #FDA

G protein-coupled receptor (GPCR) signaling alterations are linked to immune dysregulation and cancer advancement, highlighting the significance of GPCRs as potential drug targets. Utilizing our humanized GPCR models enables thorough evaluation of safety, dosing, and efficacy for your therapeutic candidates before advancing into clinical development. Check out our B-hCCR8 mice (https://lnkd.in/eyejujwm) and B-hC5AR1 mice (https://lnkd.in/edUFrqxt) #preclinical #antibody #humanizedmodel #GPCR #mousemodel #biomice #drugdiscovery #drugdevelopment #biotech #pharma

The development of successful therapies necessitates the assessment of a drug's effect on multiple cells or tissue types. Modelling these complex interactions is often acheieved at the expense of scalability, thus posing a challenge for drug development. At HUB, we set up unique organoid co-cultures to allow the development of immunomodulatory agents within the tumor microenvironment. Want to discuss how this could help your research? Join us at #AACR2024. Our organoid expert will be happy to assist you in how our proprietary technology can help you move your immunotherapy agent to the clinical trials with confidence. Click in the link below to book a meeting with us --> https://bit.ly/4atqvWf #organoids #AACR2024 #cancerresearch #tumoroids #tumororganoids #patientinalab #oncologytrials #drugdevelopment #cocultures #tumormicroenvironment #immunecells #immunotherapy #immunecheckpointinhibitors #PDL1 #KRAS

Very interesting phase II basket trial looking at using cell-free DNA to test for HER2 amplification. In this trial, patients who were HER2 amplified according to cell-free DNA had a median progression-free survival of 7.0 months when given trastuzumab deruxtecan. This does appear to be a proof of concept that shows that we might be able to start testing for HER2 via liquid biopsy, avoiding issues with tissue sampling. One issue is that 4,734 patients underwent testing, 252 were considered HER2 amplified, and 62 patients were included in the study. So overall, very few patients were considered HER2 amplified, and it's hard to conclude anything definitively from 62 patients. Trastuzumab deruxtecan does have a cytotoxic effect independent of its binding to HER2, so the question is, would this have been better than salvage chemotherapy? #enhertu #her2 https://lnkd.in/e2UBujBm